Vir Biotechnology, Inc. business relationships
Companies named in Vir Biotechnology, Inc.’s 10-K filed 2026-02-23, and public companies whose annual reports name Vir Biotechnology, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 96 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Vir Biotechnology, Inc.’s annual report 9
“Additionally, there are two known small pharmaceutical companies developing programs with various mechanisms of action, including Huahui Health and Assembly Biosciences (in partnership with Gilead).” SEC filing
“1 : Masked TCEs licensed from Sanofi” SEC filing
“Under the terms of the Sanofi Agreement, we will share with Sanofi 20% of certain future collaboration proceeds, including the upfront payment, equity premium and the portion of milestones, profit-share and royalties that exceed amounts already owed to Sanofi.” SEC filing
“Amended and Restated Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated M arch 7, 2025” SEC filing
“In October 2017, we and Alnylam Pharmaceuticals, Inc. (Alnylam) entered into a collaboration and license agreement (the Alnylam Agreement).” SEC filing
“Patent License Agreement between the Company and Xencor, Inc., dated March 25, 2020” SEC filing
“Going forward, we expect a nominal amount of license and collaboration revenue, if any, from our 2020 GSK Agreement, and we may incur negative license and collaboration revenue related to costs for ongoing required support efforts that our partner GSK leads.” SEC filing
“Additionally, there are two known small pharmaceutical companies developing programs with various mechanisms of action, including Huahui Health and Assembly Biosciences (in partnership with Gilead).” SEC filing
“Collaboration, Option, and License Agreement between the Company and Brii Biosciences Limited (previously named BiiG Therapeutics Limited), dated May 23, 2018” SEC filing
Companies whose annual reports name Vir Biotechnology, Inc. 1
“• Following the exclusive licensing agreement on the ProXTen technology platform entered into with Vir Biotechnology in” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.